Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

Referred to the House Committee on Energy and Commerce.

2026-04-06

This bill would reauthorize and expand programs designed to speed up the development and approval of treatments for ALS (amyotrophic lateral sclerosis), a serious neurological disease that causes muscle weakness and paralysis. The legislation would help patients with ALS get access to new therapies faster by streamlining the regulatory process and potentially providing funding or incentives for companies developing these treatments. The bill affects ALS patients, pharmaceutical companies working on new drugs, and the FDA's drug approval process.